Columbia, United States
Endevica Bio, founded in 2009, is making strides in the Biotechnology and Pharmaceutical industries with a focus on addressing health and wellness. The company is headquartered in the United States.
The startup's mission, encapsulated in their slogan, “Reversing cachexia and improving quality of life in cancer patients,” reflects their dedication to innovative healthcare solutions. Their lead drug candidate, a peptide therapeutic for treating cachexia related to cancer and other chronic conditions, is currently undergoing Phase 1 clinical trials in the US.
Endevica Bio recently secured a significant $10.00M Series B investment as of January 19th, 2023. This funding will likely bolster their ongoing clinical efforts and support further development activities.
The company stands out in the rapidly evolving biotech space by addressing critical unmet medical needs, presenting a compelling case for investment consideration.
